We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Global POC Diagnostics Market to Reach Nearly USD 90 Billion Due to Growing Demand for Rapid COVID-19 Test Kits

By LabMedica International staff writers
Posted on 13 Dec 2021
Print article
Illustration
Illustration

The global point of care (POC) diagnostics market is estimated to grow at a CAGR of 12.7% from approximately USD 36 billion in 2021 to nearly USD 90 billion in 2028, driven by the increasing prevalence of infectious diseases, product developments and launches, and rise in the number of CLIA-waived POC tests. However, product recalls are expected to hamper market growth.

These are the latest findings of ResearchAndMarkets (Dublin, Ireland), the world’s largest market research store.

Point of care testing (POCT) is described as medical diagnostic testing at or near the point of care that is, at time and place of patient care. The purpose of POCT is to provide immediate information to physicians about the patient's condition. POCT is an important diagnostic tool used in various locations in the hospital such as the intensive care unit (ICU), the operating room (OR), and the emergency department (ED).

Based on product, the glucose monitoring segment held the largest share of the global POC diagnostics market in 2020. However, the infectious diseases segment is estimated to register the highest CAGR of 14.1% during the forecast period. The POC diagnostics market is witnessing substantial growth amid the COVID-19 pandemic. Certain factors such as sudden rise in coronavirus infections and exponential growth in COVID-19 diagnostic kits have played a prominent role in the growth of the POC diagnostics market during the pandemic. In addition, the growing demand for rapid COVID-19 test kits for faster diagnosis at public places is also estimated to have a positive impact on market growth.

Related Links:
ResearchAndMarkets 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.